Deczuba 50 mg Injection 1's
₹3034*
MRP ₹3700
18% off
₹3145*
MRP ₹3700
15% CB
₹555 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Deczuba 50 mg Injection belongs to the group of medicines called hypomethylation agents used to treat myelodysplastic syndrome. A myelodysplastic syndrome is a group of malignancies known as myelodysplastic syndromes that occur when immature blood cells in the bone marrow do not mature or turn into healthy blood cells.
Deczuba 50 mg Injection contains ‘Decitabine’, which works by helping the bone marrow produce normal blood cells and kills abnormal cells in the bone marrow.
Decitabine should be administered to patients only in a hospital setting under the supervision of a physician qualified by training and experience to administer chemotherapeutic agents. Decitabine should usually be given for at least four cycles but may be continued if your doctor decides you will benefit from additional treatment. The most common adverse reactions of Deczuba 50 mg Injection are injection site reactions, excessive tiredness, headache, dizziness, confusion, fast heartbeat, difficulty falling asleep or staying asleep, weakness, shortness of breath, nausea, constipation, diarrhoea, vomiting, heartburn, chest discomfort and swelling of the hands, feet, ankles, lower legs, or stomach. Talk with your doctor if you experience any of these side effects persistently.
Decitabine may harm your fetus. Avoid taking Deczuba 50 mg Injection if you are pregnant or breastfeeding. You or your partner should not become pregnant while you are using decitabine. It would be best if you used birth control to prevent pregnancy in yourself or your partner during your treatment with decitabine and for two months afterwards. Call your doctor if you or your partner becomes pregnant while using decitabine. If you are breastfeeding. Do not breastfeed while you take this drug and for two weeks after your last dose. Deczuba 50 mg Injection may cause dizziness, sleepiness, tiredness, and blurred vision, so drive only if alert. Deczuba 50 mg Injection is not recommended for children below 18 years as safety and effectiveness have not been established. Inform your doctor about your health condition and medications before taking Deczuba 50 mg Injection to rule out interactions.
Deczuba 50 mg Injection belongs to the group of medicines called hypomethylation agents used to treat myelodysplastic syndrome. Deczuba 50 mg Injection contains ‘Decitabine’, which works by helping the bone marrow produce normal blood cells and kills abnormal cells in the bone marrow. On the other hand, it can treat blood cancer, known as acute myeloid leukemia (AML).
Before taking the Deczuba 50 mg Injection, let your doctor know about all your medical conditions, sensitivities, and medications you are using. Before and during your therapy, your doctor will prescribe laboratory testing on a regular basis. You may have a higher risk of infection. Hands must be washed frequently. Avoid contact with those who have illnesses, colds, or the flu. You may bleed more easily. Take precautions to avoid injury. Do not skip any scheduled dose or take other medications unless prescribed by the doctor.
Drug-Drug Interactions: Deczuba 50 mg Injection may interact with medicines used to treat rheumatoid and psoriatic arthritis (e.g. adalimumab, baricitinib, leflunomide), vaccinations (e.g. BCG vaccine, dengue vaccine, yellow fever vaccine), antipsychotic medication (e.g. clozapine).
Drug-Food Interactions: Avoid the consumption of alcoholic beverages.
Drug-Disease Interactions: Deczuba 50 mg Injection may interact with various disease conditions, including liver, kidney and haematological toxicities (Low platelet level, low count of a type of white blood cell).
Myelodysplastic syndromes: Myelodysplastic syndromes are malignancies in which immature blood cells in the bone marrow do not mature and do not become healthy blood cells. Abnormalities in blood cells and bone marrow distinguish the many forms of myelodysplastic syndromes.
Alcohol
Unsafe
You are recommended to avoid alcohol consumption while on treatment with Deczuba 50 mg Injection as it might cause increased dizziness.
Pregnancy
Unsafe
Deczuba 50 mg Injection should not be used during pregnancy. So, inform your doctor if you are pregnant or suspect pregnancy. You or your partner must use a reliable form of contraception to prevent pregnancy while taking these medications.
Breast Feeding
Unsafe
Deczuba 50 mg Injection should not be used in breastfeeding. Discuss with your doctor if you have any concerns.
Driving
Unsafe
Deczuba 50 mg Injection may cause dizziness, sleepiness, and blurred vision. Do not drive or operate heavy machinery unless you are alert.
Liver
Caution
Inform your doctor before receiving the Deczuba 50 mg Injection if you have had a liver impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.
Kidney
Caution
Inform your doctor before receiving the Deczuba 50 mg Injection if you have had a kidney impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.
Children
Unsafe
Deczuba 50 mg Injection is not recommended for children below 18 years as the safety and effectiveness have not been established.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes